Grand Cayman, Cayman Islands Panacea Venture is the famous VC, which was founded in 2017. The leading representative office of defined VC is situated in the Grand Cayman. The company was established in North America in Cayman Islands.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The important activity for fund was in 2019. Speaking about the real fund results, this VC is 20 percentage points more often commits exit comparing to other organizations. The typical startup value when the investment from Panacea Venture is 50-100 millions dollars. The fund is constantly included in 2-6 investment rounds annually.
Besides them, we counted 2 critical employees of this fund in our database.
For fund there is no match between the country of its foundation and the country of its the most frequent investments - China. The fund has no specific favorite in a number of founders of portfolio startups. We can highlight the next thriving fund investment areas, such as Health Care, Biopharma. Moreover, a startup needs to be at the age of 1 and less years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Oncologie, TriArm Therapeutics, Tactiva Therapeutics.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Panacea Venture, startups are often financed by Volcanics Venture, Redhill Capital, Pivotal bioVenture Partners China. The meaningful sponsors for the fund in investment in the same round are EFung Capital, Viventures, Virtus Inspire Ventures. In the next rounds fund is usually obtained by Innovate UK, Duchenne UK.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Atlant Fonder AB | Stockholm, Stockholm County, Sweden |
| C.D.S Italy | - |
| Cat Financial | Nashville, Tennessee, United States |
| Divergence Ventures | - |
| Dquadrat Equity Partner | - |
| Efficiency | Alicante, Comunidad Valenciana, Spain |
| G100 Capital | - |
| Gaea Technology | China, Guangdong, Shenzhen |
| Gains Associates | France, Ile-de-France, Paris |
| High Park Angels | Canada, Ontario, Toronto |
| LyondellBasell Industries | England, London, United Kingdom |
| Panther Angels | Cockeysville, Maryland, United States |
| Samch Capital | China, Shanghai |
| Soho Strategy | England, London, United Kingdom |
| Sud Rhone-Alpes Capital | France, Grenoble, Rhone-Alpes |
| Wobbly-Door Ventures | California, Palo Alto, United States |
| Zhoushan Hongyi Guquan Touzi | China, Dinghai, Zhejiang |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Actym | $25M | 18 Oct 2023 | San Francisco, California, United States | ||
Domain Therapeutics | $46M | 10 May 2022 | France, Grand Est, France | ||
Inmagene Biopharmaceuticals | $100M | 01 Jun 2021 | Zhangdian District, Shandong, China | ||
Chime Biologics | $190M | 25 Mar 2021 | Jiang'an District, Hubei, China | ||
Inmagene Biopharmaceuticals | $21M | 08 Nov 2020 | Zhangdian District, Shandong, China | ||
XW Laboratories | $40M | 18 Sep 2020 | Jiang'an District, Hubei, China | ||
Actym | $34M | 27 Apr 2020 | San Francisco, California, United States | ||
| $20M | 19 Jul 2019 | Beijing | |||
| $15M | 09 Jul 2019 | Liaoning |
– Chime Biologics secures US$190m in Series A+ financing.
– The round was led by VMS Group, followed by Fidelity International and Panacea Venture.
– Chime Biologics has built a GE KuBio modular bio-manufacturing facility in Wuhan Bio-Lake biotech industry development zone of China.
– The company provides outsourcing services for biopharmaceutical development and manufacturing.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Actym | $25M | 18 Oct 2023 | San Francisco, California, United States | ||
Domain Therapeutics | $46M | 10 May 2022 | France, Grand Est, France | ||
Inmagene Biopharmaceuticals | $100M | 01 Jun 2021 | Zhangdian District, Shandong, China | ||
Chime Biologics | $190M | 25 Mar 2021 | Jiang'an District, Hubei, China | ||
Inmagene Biopharmaceuticals | $21M | 08 Nov 2020 | Zhangdian District, Shandong, China | ||
XW Laboratories | $40M | 18 Sep 2020 | Jiang'an District, Hubei, China | ||
Actym | $34M | 27 Apr 2020 | San Francisco, California, United States | ||
| $20M | 19 Jul 2019 | Beijing | |||
| $15M | 09 Jul 2019 | Liaoning |
